We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF and Tosoh Europe N.V. Sign Distribution Agreement for Quo-Test HbA1c POC Analyzer in Middle East and Africa

By LabMedica International staff writers
Posted on 15 May 2020
Print article
Image: EKF’s Quo-Test analyzer (Photo courtesy of EKF Diagnostics)
Image: EKF’s Quo-Test analyzer (Photo courtesy of EKF Diagnostics)
EKF Diagnostics has signed a three-year distribution agreement with (Cardiff, UK) Tosoh Europe N.V. (Tessenderlo, Belgium) for the distribution of its Quo-Test HbA1c point-of-care (POC) analyzer in the Middle East and Africa.

Tosoh Bioscience division is one of the largest global manufacturers of high-performance liquid chromatography (HPLC) equipment for glycated hemoglobin analysis predominantly in core laboratories. Tosoh’s analyzers are frequently used to benchmark and validate POC devices such as Quo-Test. As a desktop analyzer designed for simple and reliable HbA1c measurement for monitoring and managing diabetes in POC settings, such as diabetes clinics and doctors’ surgeries, EKF’s Quo-Test analyzer complements Tosoh’s HPLC technology.

Quo-Test is fully automated and quantifies HbA1c from a 4μL sample taken from a finger prick or venous whole blood. Unaffected by most hemoglobin variants, lab-quality results are available within four minutes and reported in IFCC and DCCT standard units. Also facilitating its use as a POC analyzer, step-by-step instructions are displayed on Quo-Test’s multi-lingual display, minimizing staff training time and minimizing user-related errors.

EKF’s Quo-Test distribution agreement with Tosoh Europe will allow both the companies to work in markets they have previously been unable to access and provide Tosoh Europe with the opportunity to offer new services to suit changing customer requirements. After the initial three-year term for the Middle East and Africa, the distribution agreement has a rolling one-year renewal with the option to extend the agreement into EU countries as required.

“We are delighted to partner with Tosoh Europe as they expand their need for point-of-care HbA1c analysis in a time where those suffering from diabetes are at greater risk,” said Julian Baines, CEO of EKF. “Tosoh is a leading HPLC brand and its analyzers are considered to be the gold standard when validating POC products such as EKF’s Quo-Test. For them to choose our analyzer to complement their lab-based HPLC analyzers for HbA1c testing is a great endorsement of our technology.”




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.